Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 11 | 2026 | 432 | 2.430 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 7 | 2022 | 7 | 1.620 |
Why?
|
| Auditory Perception | 5 | 2018 | 5 | 1.610 |
Why?
|
| Hearing Loss, Noise-Induced | 3 | 2022 | 5 | 1.490 |
Why?
|
| Homosexuality, Male | 6 | 2026 | 83 | 1.360 |
Why?
|
| Anura | 6 | 2021 | 12 | 1.280 |
Why?
|
| Male | 28 | 2026 | 3671 | 1.190 |
Why?
|
| Deafness | 4 | 2023 | 6 | 1.190 |
Why?
|
| Pre-Exposure Prophylaxis | 6 | 2026 | 67 | 1.180 |
Why?
|
| Sexually Transmitted Diseases | 3 | 2025 | 35 | 1.120 |
Why?
|
| Prisoners | 2 | 2025 | 31 | 1.110 |
Why?
|
| Substance-Related Disorders | 2 | 2025 | 102 | 1.010 |
Why?
|
| Auditory Threshold | 5 | 2022 | 5 | 0.950 |
Why?
|
| Hearing Loss | 3 | 2020 | 13 | 0.930 |
Why?
|
| Female | 20 | 2026 | 4060 | 0.920 |
Why?
|
| Animals | 20 | 2023 | 1875 | 0.870 |
Why?
|
| Humans | 27 | 2026 | 6794 | 0.830 |
Why?
|
| Noise | 4 | 2022 | 4 | 0.820 |
Why?
|
| Diet | 5 | 2023 | 111 | 0.750 |
Why?
|
| Sexual and Gender Minorities | 4 | 2024 | 49 | 0.750 |
Why?
|
| Young Adult | 9 | 2026 | 567 | 0.730 |
Why?
|
| Vocalization, Animal | 4 | 2017 | 4 | 0.720 |
Why?
|
| Adult | 11 | 2026 | 2113 | 0.640 |
Why?
|
| Sex Factors | 3 | 2017 | 155 | 0.630 |
Why?
|
| Physician Assistants | 3 | 2024 | 12 | 0.610 |
Why?
|
| Anti-HIV Agents | 4 | 2026 | 102 | 0.610 |
Why?
|
| Hyperkinesis | 1 | 2018 | 1 | 0.580 |
Why?
|
| Cochlear Nucleus | 1 | 2018 | 1 | 0.580 |
Why?
|
| Spiral Ganglion | 1 | 2018 | 2 | 0.570 |
Why?
|
| Behavior, Animal | 1 | 2018 | 30 | 0.560 |
Why?
|
| Middle Aged | 11 | 2026 | 2108 | 0.550 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2021 | 279 | 0.550 |
Why?
|
| Bias | 1 | 2017 | 5 | 0.540 |
Why?
|
| Biomedical Research | 1 | 2017 | 34 | 0.520 |
Why?
|
| Hearing | 5 | 2023 | 5 | 0.480 |
Why?
|
| Mice, Inbred CBA | 5 | 2022 | 5 | 0.470 |
Why?
|
| Mice | 7 | 2023 | 746 | 0.460 |
Why?
|
| Peripheral Nervous System | 1 | 2015 | 2 | 0.450 |
Why?
|
| Acoustic Stimulation | 6 | 2022 | 6 | 0.450 |
Why?
|
| Siblings | 2 | 2024 | 7 | 0.420 |
Why?
|
| Body Size | 1 | 2014 | 8 | 0.420 |
Why?
|
| Los Angeles | 5 | 2026 | 321 | 0.360 |
Why?
|
| Hair Cells, Auditory | 3 | 2020 | 3 | 0.340 |
Why?
|
| United States | 6 | 2024 | 1019 | 0.290 |
Why?
|
| Leadership | 3 | 2023 | 22 | 0.290 |
Why?
|
| Pandemics | 3 | 2023 | 87 | 0.290 |
Why?
|
| Sexual Behavior | 3 | 2025 | 100 | 0.270 |
Why?
|
| Peer Group | 2 | 2025 | 34 | 0.270 |
Why?
|
| Neurons | 3 | 2017 | 50 | 0.250 |
Why?
|
| Cross-Sectional Studies | 3 | 2026 | 506 | 0.250 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2024 | 153 | 0.240 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2026 | 4 | 0.240 |
Why?
|
| Patient Compliance | 1 | 2026 | 48 | 0.240 |
Why?
|
| Aging | 3 | 2022 | 105 | 0.230 |
Why?
|
| Transgender Persons | 1 | 2025 | 24 | 0.230 |
Why?
|
| Sexual Partners | 2 | 2022 | 49 | 0.230 |
Why?
|
| Social Support | 1 | 2025 | 67 | 0.220 |
Why?
|
| Motivational Interviewing | 1 | 2024 | 5 | 0.220 |
Why?
|
| Disease Models, Animal | 2 | 2022 | 231 | 0.220 |
Why?
|
| Nutrition Surveys | 2 | 2021 | 67 | 0.220 |
Why?
|
| Hypertension | 1 | 2026 | 147 | 0.220 |
Why?
|
| Cochlea | 2 | 2022 | 3 | 0.210 |
Why?
|
| Vestibular Diseases | 1 | 2023 | 1 | 0.210 |
Why?
|
| CHARGE Syndrome | 1 | 2023 | 1 | 0.210 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2023 | 3 | 0.210 |
Why?
|
| Abnormalities, Multiple | 1 | 2023 | 6 | 0.210 |
Why?
|
| Face | 1 | 2023 | 4 | 0.210 |
Why?
|
| Aged | 4 | 2026 | 1539 | 0.210 |
Why?
|
| Hematologic Diseases | 1 | 2023 | 5 | 0.210 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2024 | 72 | 0.210 |
Why?
|
| Food | 1 | 2023 | 8 | 0.200 |
Why?
|
| Faculty | 1 | 2023 | 10 | 0.200 |
Why?
|
| Mentoring | 1 | 2023 | 12 | 0.190 |
Why?
|
| Physicians | 1 | 2023 | 49 | 0.190 |
Why?
|
| Nutrition Assessment | 1 | 2023 | 26 | 0.190 |
Why?
|
| Exercise | 1 | 2023 | 55 | 0.190 |
Why?
|
| Education, Medical | 1 | 2022 | 20 | 0.190 |
Why?
|
| Continuity of Patient Care | 1 | 2022 | 19 | 0.190 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 7 | 0.180 |
Why?
|
| Minority Groups | 1 | 2022 | 63 | 0.180 |
Why?
|
| Reflex, Startle | 1 | 2022 | 1 | 0.180 |
Why?
|
| Central Nervous System Stimulants | 1 | 2022 | 10 | 0.180 |
Why?
|
| Chiroptera | 1 | 2021 | 1 | 0.180 |
Why?
|
| Echolocation | 1 | 2021 | 1 | 0.180 |
Why?
|
| Sex Characteristics | 2 | 2020 | 39 | 0.180 |
Why?
|
| Mexican Americans | 1 | 2021 | 14 | 0.170 |
Why?
|
| Psychoacoustics | 3 | 2020 | 3 | 0.170 |
Why?
|
| Animal Communication | 1 | 2021 | 1 | 0.170 |
Why?
|
| Curcumin | 1 | 2020 | 8 | 0.170 |
Why?
|
| Fatty Liver | 1 | 2021 | 59 | 0.170 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2020 | 10 | 0.170 |
Why?
|
| Mole Rats | 1 | 2020 | 1 | 0.170 |
Why?
|
| Species Specificity | 3 | 2015 | 17 | 0.170 |
Why?
|
| Nerve Degeneration | 1 | 2020 | 2 | 0.170 |
Why?
|
| Analgesics, Opioid | 2 | 2013 | 58 | 0.170 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 7 | 0.170 |
Why?
|
| Adaptation, Physiological | 1 | 2020 | 13 | 0.170 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2020 | 3 | 0.160 |
Why?
|
| RNA, Long Noncoding | 1 | 2020 | 20 | 0.160 |
Why?
|
| Health Status Disparities | 1 | 2021 | 83 | 0.160 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 72 | 0.160 |
Why?
|
| Visual Cortex | 1 | 2018 | 1 | 0.150 |
Why?
|
| Long-Term Potentiation | 1 | 2018 | 1 | 0.150 |
Why?
|
| Visual Perception | 1 | 2018 | 2 | 0.150 |
Why?
|
| Thalamus | 1 | 2018 | 3 | 0.150 |
Why?
|
| Sexism | 1 | 2018 | 5 | 0.140 |
Why?
|
| Inferior Colliculi | 1 | 2017 | 1 | 0.130 |
Why?
|
| Rana clamitans | 1 | 2017 | 1 | 0.130 |
Why?
|
| Nonlinear Dynamics | 1 | 2017 | 2 | 0.130 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2017 | 2 | 0.130 |
Why?
|
| Catecholamines | 1 | 2017 | 7 | 0.130 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2017 | 4 | 0.130 |
Why?
|
| Reaction Time | 2 | 2014 | 12 | 0.130 |
Why?
|
| Surveys and Questionnaires | 3 | 2023 | 280 | 0.130 |
Why?
|
| Feedback, Physiological | 1 | 2014 | 4 | 0.110 |
Why?
|
| Models, Biological | 1 | 2014 | 64 | 0.110 |
Why?
|
| Sound Localization | 1 | 2014 | 1 | 0.110 |
Why?
|
| Tympanic Membrane | 1 | 2014 | 3 | 0.110 |
Why?
|
| Feasibility Studies | 2 | 2024 | 44 | 0.110 |
Why?
|
| Electrophysiology | 1 | 2014 | 8 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2014 | 63 | 0.100 |
Why?
|
| Caudate Nucleus | 1 | 2013 | 1 | 0.100 |
Why?
|
| Macaca fascicularis | 1 | 2013 | 8 | 0.100 |
Why?
|
| Nucleus Accumbens | 1 | 2013 | 9 | 0.100 |
Why?
|
| Incidence | 2 | 2026 | 197 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 64 | 0.100 |
Why?
|
| Receptors, Opioid, kappa | 2 | 2013 | 5 | 0.100 |
Why?
|
| Receptors, Opioid, mu | 2 | 2013 | 19 | 0.100 |
Why?
|
| Educational Status | 2 | 2023 | 61 | 0.090 |
Why?
|
| Child | 2 | 2023 | 524 | 0.080 |
Why?
|
| Research Design | 2 | 2023 | 41 | 0.080 |
Why?
|
| Adolescent | 2 | 2022 | 869 | 0.070 |
Why?
|
| Opioid-Related Disorders | 1 | 2008 | 17 | 0.070 |
Why?
|
| Lung | 2 | 2021 | 106 | 0.060 |
Why?
|
| Delayed-Action Preparations | 1 | 2026 | 8 | 0.060 |
Why?
|
| Injections | 1 | 2026 | 20 | 0.060 |
Why?
|
| Computer Simulation | 1 | 2026 | 26 | 0.060 |
Why?
|
| Urban Population | 1 | 2026 | 85 | 0.060 |
Why?
|
| Medication Adherence | 1 | 2026 | 64 | 0.060 |
Why?
|
| Motivation | 1 | 2024 | 42 | 0.050 |
Why?
|
| Pilot Projects | 1 | 2024 | 89 | 0.050 |
Why?
|
| Causality | 1 | 2023 | 8 | 0.050 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2023 | 5 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2024 | 285 | 0.050 |
Why?
|
| Food Supply | 1 | 2023 | 11 | 0.050 |
Why?
|
| Geriatric Assessment | 1 | 2023 | 13 | 0.050 |
Why?
|
| Intention | 1 | 2023 | 20 | 0.050 |
Why?
|
| Eating | 1 | 2023 | 31 | 0.050 |
Why?
|
| HIV | 1 | 2022 | 16 | 0.050 |
Why?
|
| Chronic Disease | 1 | 2023 | 167 | 0.050 |
Why?
|
| Sustained Virologic Response | 1 | 2022 | 7 | 0.050 |
Why?
|
| Faculty, Medical | 1 | 2022 | 17 | 0.050 |
Why?
|
| Viral Load | 1 | 2022 | 26 | 0.050 |
Why?
|
| Depression | 1 | 2023 | 128 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2021 | 66 | 0.040 |
Why?
|
| Benzeneacetamides | 2 | 2013 | 2 | 0.040 |
Why?
|
| Pyrrolidines | 2 | 2013 | 4 | 0.040 |
Why?
|
| Fentanyl | 2 | 2013 | 7 | 0.040 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2021 | 1 | 0.040 |
Why?
|
| Sirolimus | 1 | 2020 | 6 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 14 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2020 | 27 | 0.040 |
Why?
|
| Base Sequence | 1 | 2020 | 65 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 40 | 0.040 |
Why?
|
| Neoplastic Stem Cells | 1 | 2020 | 24 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2020 | 3 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 6 | 0.040 |
Why?
|
| Selection, Genetic | 1 | 2020 | 3 | 0.040 |
Why?
|
| Africa | 1 | 2020 | 12 | 0.040 |
Why?
|
| Prevalence | 1 | 2021 | 259 | 0.040 |
Why?
|
| Unsafe Sex | 1 | 2020 | 21 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 156 | 0.040 |
Why?
|
| Disease Progression | 1 | 2020 | 170 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 88 | 0.040 |
Why?
|
| MicroRNAs | 1 | 2020 | 54 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2020 | 143 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2020 | 246 | 0.040 |
Why?
|
| Inhibitory Postsynaptic Potentials | 1 | 2018 | 2 | 0.040 |
Why?
|
| Interneurons | 1 | 2018 | 2 | 0.040 |
Why?
|
| Sensory Deprivation | 1 | 2018 | 2 | 0.040 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2018 | 5 | 0.040 |
Why?
|
| Risk Factors | 1 | 2021 | 767 | 0.040 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2018 | 18 | 0.040 |
Why?
|
| Auditory Pathways | 1 | 2017 | 1 | 0.030 |
Why?
|
| Sexual Behavior, Animal | 1 | 2017 | 2 | 0.030 |
Why?
|
| Models, Neurological | 1 | 2017 | 3 | 0.030 |
Why?
|
| Action Potentials | 1 | 2017 | 6 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 258 | 0.030 |
Why?
|
| Methylation | 1 | 2017 | 9 | 0.030 |
Why?
|
| Neuromuscular Nondepolarizing Agents | 1 | 2014 | 1 | 0.030 |
Why?
|
| Tubocurarine | 1 | 2014 | 1 | 0.030 |
Why?
|
| Brain Stem | 1 | 2014 | 3 | 0.030 |
Why?
|
| Immobilization | 1 | 2014 | 4 | 0.030 |
Why?
|
| Texas | 1 | 2014 | 9 | 0.030 |
Why?
|
| Weight Gain | 1 | 2014 | 28 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 112 | 0.030 |
Why?
|
| Space Perception | 1 | 2014 | 1 | 0.030 |
Why?
|
| Vibration | 1 | 2014 | 2 | 0.030 |
Why?
|
| Pressure | 1 | 2014 | 7 | 0.030 |
Why?
|
| Motor Activity | 1 | 2014 | 26 | 0.030 |
Why?
|
| Wakefulness | 1 | 2013 | 5 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2013 | 19 | 0.030 |
Why?
|
| Restraint, Physical | 1 | 2013 | 3 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2013 | 25 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 25 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2013 | 19 | 0.020 |
Why?
|
| Hydrocortisone | 1 | 2013 | 33 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 2013 | 60 | 0.020 |
Why?
|
| Reinforcement Schedule | 1 | 2008 | 2 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2008 | 9 | 0.020 |
Why?
|
| Self Administration | 1 | 2008 | 6 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2008 | 8 | 0.020 |
Why?
|
| Conditioning, Operant | 1 | 2008 | 17 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2008 | 27 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2008 | 51 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 155 | 0.020 |
Why?
|